Reliability of Muscle Strength and Activation Assessment Tools and Effects of an Online Therapeutic Exercise Program in Patients With Chronic Kidney Disease

December 5, 2025 updated by: Alejandro Caña Pino, University of Extremadura
This research aims to evaluate the reliability and reproducibility of muscle strength and activation measurement tools, including isokinetic dynamometry and surface electromyography, in patients with chronic kidney disease (CKD). Additionally, the study will assess the feasibility and potential benefits of an online therapeutic exercise program supervised by physiotherapists.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Patients with chronic kidney disease experience progressive muscle weakness and reduced physical capacity due to systemic inflammation, metabolic acidosis, and inactivity.

This two-phase observational and interventional study, conducted in collaboration with the ALCER Association (Badajoz and Cáceres, Spain), will:

  1. Determine the test-retest reliability of muscle assessment tools (isokinetic dynamometer, surface electromyography, and handheld dynamometry).
  2. Implement and evaluate an online therapeutic exercise program supervised by physiotherapists.

The project aims to provide valid and reliable protocols for neuromuscular assessment in CKD patients and explore the feasibility of remote therapeutic exercise.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
    • Cáceres
      • Cáceres, Cáceres, Spain, 10003
        • Facultad de Enfermería y Terapia Ocupacional

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • ≥18 years old.
  • Diagnosis of chronic kidney disease (hemodialysis, peritoneal dialysis, or kidney transplant).
  • Member of ALCER Association (Badajoz or Cáceres).
  • Medical clearance for physical testing/exercise.

Exclusion Criteria:

  • Severe cognitive or communication impairment.
  • Unstable cardiovascular or musculoskeletal conditions.
  • Refusal to provide informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Reliability Assessment
Test-retest reliability of isokinetic and surface EMG measurements in upper limb, trunk, and lower limb
Device: Reliability Assessment
Device: Isokinetic dynamometer and mDurance® surface EMG Test-retest reliability of isokinetic and surface EMG measurements in upper limb, trunk, and lower limb
Experimental: Online Therapeutic Exercise
8-10 week supervised online program including resistance and mobility exercises
Behavioral: Online Therapeutic Exercise
Behavioral: Online therapeutic exercise program 8-10 week supervised online program including resistance and mobility exercises

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Test-retest reliability of surface EMG (Electromiography) activation.
Time Frame: 7-10 days
RMS (root mean square). microvolts
7-10 days
Test-retest reliability of isokinetic strength
Time Frame: 7-10 days
Intraclass Correlation Coefficient - ICC. Strength (kilograms)
7-10 days
Change in handgrip and limb strength measured by VALD dynamometry
Time Frame: Baseline and 12 weeks
strength (kilograms)
Baseline and 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Extremadura

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 7, 2025

Primary Completion (Estimated)

January 30, 2026

Study Completion (Estimated)

May 15, 2026

Study Registration Dates

First Submitted

December 5, 2025

First Submitted That Met QC Criteria

December 5, 2025

First Posted (Actual)

December 18, 2025

Study Record Updates

Last Update Posted (Actual)

December 18, 2025

Last Update Submitted That Met QC Criteria

December 5, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 071125

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Renal Insufficiency, Chronic

Clinical Trials on Reliability Assessment

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe